Teligent to Pursue Asset Sale through Voluntary Chapter 11 Process Company is arranging $12 million debtor-in-possession financing from its senior secured lenders and access to its cash...
–Update on FDA Inspection of Buena Facility–Assessing New Growth Opportunities in Injectables–Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time –Dial in: (877...
BUENA, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey based generics pharmaceutical company, today announced they will hold a...
Scheduled to Reconvene on July 21, 2021Company Urgently Encourages Stockholders to Vote BUENA, N.J., June 30, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based...
Scheduled to Reconvene on June 30, 2021Company Urgently Encourages Stockholders to Vote BUENA, N.J., June 18, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based...
–Continued Remediation Progress Being Made–Reiterating Prior Guidance of Informing FDA on Inspection Readiness During 3Q2021–Conference Call to Be Held on May 25, 2021 at 4:30 pm Eastern Standard...
– Significantly strengthened balance sheet and cash position – Continued FDA Warning Letter remediation efforts – Anticipate informing FDA on inspection readiness during 3Q2021 – Conference Call...
BUENA, N.J., April 15, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, today announced the...
Teligent, Inc. Announces Appointment of Carter Pate to Board of Directors Experienced Board Member and Investment Executive Joins Teligent, Effective Immediately PR Newswire BUENA, N.J., Feb. 23...
Teligent, Inc. Announces Appointment of William S. Marth to Board of Directors Generic Pharmaceutical and Contract Manufacturing Industry Leader Joins Teligent Board, Effective Immediately PR...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.